Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.

Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Therapeutics Pubmed

Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.

Clinical Therapeutics , Volume 34 (3): 160009 – Jul 16, 2012

Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.

Clinical Therapeutics , Volume 34 (3): 160009 – Jul 16, 2012

Loading next page...
 
/lp/pubmed/efficacy-and-tolerability-of-fimasartan-a-new-angiotensin-receptor-WTDn0BSdqm

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0149-2918
DOI
10.1016/j.clinthera.2012.01.024
pmid
22381711

Abstract

Journal

Clinical TherapeuticsPubmed

Published: Jul 16, 2012

There are no references for this article.